IL326149A - נוגדנים אנטי- acvr2b ושימושים בהם - Google Patents

נוגדנים אנטי- acvr2b ושימושים בהם

Info

Publication number
IL326149A
IL326149A IL326149A IL32614926A IL326149A IL 326149 A IL326149 A IL 326149A IL 326149 A IL326149 A IL 326149A IL 32614926 A IL32614926 A IL 32614926A IL 326149 A IL326149 A IL 326149A
Authority
IL
Israel
Prior art keywords
acvr2b
antibodies
acvr2b antibodies
Prior art date
Application number
IL326149A
Other languages
English (en)
Original Assignee
Laekna Therapeutics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laekna Therapeutics Shanghai Co Ltd filed Critical Laekna Therapeutics Shanghai Co Ltd
Publication of IL326149A publication Critical patent/IL326149A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL326149A 2023-08-01 2024-07-31 נוגדנים אנטי- acvr2b ושימושים בהם IL326149A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023110569 2023-08-01
PCT/CN2024/108822 WO2025026353A1 (en) 2023-08-01 2024-07-31 Anti-acvr2b antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL326149A true IL326149A (he) 2026-03-01

Family

ID=94394268

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326149A IL326149A (he) 2023-08-01 2024-07-31 נוגדנים אנטי- acvr2b ושימושים בהם

Country Status (5)

Country Link
CN (1) CN121909215A (he)
AU (1) AU2024317260A1 (he)
IL (1) IL326149A (he)
TW (1) TW202513591A (he)
WO (1) WO2025026353A1 (he)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
LT3600415T (lt) * 2017-03-24 2025-12-29 Novartis Ag Antikūnas prieš ii tipo aktivino receptorių, skirtas naudoti širdies nepakankamumo gydymui
JP7669291B2 (ja) * 2019-05-30 2025-04-28 アクセレロン ファーマ インコーポレーテッド Ａｃｔｒｉｉ結合性タンパク質及びその使用
US20230220085A1 (en) * 2020-02-28 2023-07-13 The Brigham And Women’S Hospital, Inc. Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
JP2024524301A (ja) * 2021-07-02 2024-07-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用
TW202328190A (zh) * 2021-09-03 2023-07-16 大陸商來凱醫藥科技（上海）有限公司 抗acvr2a抗體及其用途

Also Published As

Publication number Publication date
CN121909215A (zh) 2026-04-21
TW202513591A (zh) 2025-04-01
AU2024317260A1 (en) 2026-02-12
WO2025026353A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
IL308808A (he) נוגדנים נגד ccr8 ושימושים שלהם
GB2610467B (en) Anti-CLL1 antibody and application thereof
GB202017058D0 (en) Antibodies and uses thereof
IL319931A (he) נוגדנים אנטי- cd122 ושימושים בהם
IL307267A (he) נוגדני anti-cd122 ושימושיהם
IL310662A (he) נוגדנים אנטי- cd161ושימושים בהם
IL307940A (he) נוגדנים אנטי- adgre2ושימושים בהם
IL308382A (he) נוגדנים אנטי- cd276חדשים ושימושים בהם
IL320586A (he) נוגדן נגד trem2 ושימושים שלו
LT4274851T (lt) Anti-gprc5d monokloniniai antikūnai ir jų panaudojimas
IL317391A (he) נוגדנים חדשים אנטי- lilrb4ושימושים בהם
IL307939A (he) נוגדנים אנטי- clec12aושימושים בהם
EP4464722A4 (en) ANTIBODIES AND THEIR USE
IL319145A (he) נוגדנים חדשים אנטי- lilrb2ושימושים בהם
EP4490199A4 (en) MODIFIED ANTIBODIES AND THEIR USES
IL316510A (he) נוגדן אנטי-b7h3 ושימושיו
IL304412A (he) נוגדנים כנגד cd112r ושימושים בהם
IL312584A (he) נוגדני anti-vista ושימושים בהם
IL320972A (he) נוגדנים אנטי-tfr1 ושימושים בהם
IL310810A (he) נוגדנים אנטי- acvr2a ושימושים בהם
IL317849A (he) נוגדנים חד-שבטיים אנטי- slc34a2ושימושים בהם
EP4437000A4 (en) ANTI-TREM2 ANTIBODY AND ITS USES
IL307233A (he) נוגדנים אנטי- sema3aושימושים בהם
GB202303531D0 (en) Antibodies and uses thereof
EP4493597A4 (en) Masp-2-targetting antibodies and uses thereof